1 / 19

Pediatric Research in Maryland: Implications of the Krieger Case

Pediatric Research in Maryland: Implications of the Krieger Case. Jack Schwartz Director of Health Policy Maryland AG’s Office jschwartz@oag.state.md.us. The Krieger Study: Objective. Efficacy of affordable lead abatement 3 groups of houses: varying levels of abatement

owena
Download Presentation

Pediatric Research in Maryland: Implications of the Krieger Case

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pediatric Research in Maryland: Implications of the Krieger Case Jack Schwartz Director of Health Policy Maryland AG’s Office jschwartz@oag.state.md.us

  2. The Krieger Study: Objective • Efficacy of affordable lead abatement • 3 groups of houses: varying levels of abatement • 2 groups of control houses • supposedly fully abated • no lead paint ever used

  3. The Krieger Study: Methods • Testing for lead blood levels • Testing for environmental lead levels • dust • soil • water • Questionnaires

  4. Plaintiff #1: Ericka Grimes • Infant, entered study via mother’s consent • House was in control group (fully abated) • Dust sample testing  lead “hot spots” • No disclosure for 9 months • Found to have EBL

  5. Plaintiff #2: Myron Higgins • 4 y/o, entered study via mother’s consent • House was in an intervention group • Found to have EBL

  6. The plaintiffs’ case • Negligence claims • improper abatement methods • failure to warn • Ericka and Myron win only if Krieger: • had a legally recognized duty to them • breached that duty • by the breach, caused them injury

  7. Krieger’s short-lived win • Krieger’s argument: no duty owed • “Even if what the plaintiffs say were true, they still lose.” • Trial court agrees • grants Krieger’s motion for summary judgment • No trial • No factual record except plaintiffs’ allegations

  8. Issue on appeal: existence of duty • Court of Appeals reverses trial court • Krieger did have a duty of care • Sources: • consent document = contract • nature of “nontherapeutic” research • federal regulations • Nuremberg Code

  9. Holding on parental authority • Standard = best interest of the child • Court’s view of the Krieger research • Healthy children; no personal benefit • Risk of permanent, serious harm • Participation could not be in child’s best interest • Therefore, no parental authority to consent

  10. Bioethics commentary • Krieger research deemed unethical • disregard of potential harm to subjects • inadequate informed consent • Hopkins IRB deemed unethical • regarded as an endemic problem • Researchers had conflicts of interest • financial and scientific incentives

  11. Lessons of the case for pediatric researchers • Consider issue of parental authority • suggested algorithm • Describe risks and benefits fairly and fully in protocol • Conduct genuine informed consent process • Ensure provision of information to parents • as promised • if material to decision whether child should continue in research

  12. Step 1: Any therapeutic procedures involved? • Therapeutic = evidence-based possibility of direct medical benefit • Nontherapeutic = done solely to answer the scientific question • Weijer C & Miller PB. When are research risks reasonable in relation to anticipated benefits? Nature Med 2004; 10: 570-73. • If NO  • Parental authority probably limited to minimal risk • If YES  • To Step 2

  13. Step 2: Clinical equipoise? • Are therapeutic procedures consistent with competent medical care? • If NO  • No parental authority • Not in child’s best interest to forgo preferable care • If YES  • To Step 3

  14. Step 3: Potential direct benefits worth the risk? • Are risks of therapeutic procedures justified by prospect of direct benefit? • If NO  • No parental authority • If YES  • To Step 4

  15. Step 4: Risk of nontherapeutic procedures minimized? • Are risks of nontherapeutic procedures minimized consistent with sound scientific design? • If NO  • No parental authority • If YES  • To Step 5

  16. Step 5: Risk of nontherapeutic procedures justified? • Are risks of nontherapeutic procedures no more than a minor increase over minimal and justified by scientific value? • If NO  • No parental authority • If YES  • Parental permission allowed

  17. Applying the analysis: Phase 1 oncology trials • Is test article a therapeutic procedure? • By FDA definition, not an efficacy trial • But: what if no clinical alternative for hope of remission? • Depending on facts about child, research, and alternatives: • Answer might be “Yes” to all • Parental best interest judgment possible

  18. Applying the analysis: prophylactic vaccine trials • Is test article a therapeutic procedure? • Therapeutic for healthy subjects? • Maybe, depending on risk of future disease • If IRB finds it not a therapeutic procedure: • > minimal risk • No parental authority • If IRB finds it a therapeutic procedure: • Answer might be “Yes” to all • Parental best interest judgment possible

  19. Applying the analysis: epidemiology • Probably no therapeutic procedures • What are risks of the nontherapeutic procedures? • Typical questionnaire = minimal risk • Typical phlebotomy = minimal risk • Identification of heightened genetic risk = more than minimal risk?

More Related